A pioneering clinical trial in Geelong is exploring an unconventional treatment for long COVID: faecal transplants. The study, led by researchers at Barwon Health, aims to determine whether transferring gut bacteria from healthy donors can alleviate the persistent symptoms experienced by many COVID-19 survivors.
Understanding Long COVID
Long COVID refers to a range of symptoms that continue for weeks or months after the initial infection. These can include fatigue, brain fog, shortness of breath, and digestive issues. The condition affects millions worldwide, and effective treatments remain elusive.
Recent research has highlighted a link between gut health and COVID-19 severity. The virus can disrupt the gut microbiome, leading to long-term complications. This has prompted scientists to investigate whether restoring a healthy balance of gut bacteria could help.
The Trial Details
The Geelong trial will involve 30 participants who have experienced long COVID symptoms for at least three months. Half will receive faecal transplants via capsules, while the other half will receive a placebo. Neither the participants nor the researchers will know who receives the actual treatment until the study concludes.
Dr. Sarah Johnson, lead investigator, explained: 'We know that the gut microbiome plays a crucial role in immune function. By replenishing it with healthy bacteria, we hope to reduce inflammation and improve symptoms.'
How Faecal Transplants Work
Faecal microbiota transplantation (FMT) involves processing stool from a healthy donor to extract beneficial bacteria. This material is then encapsulated or delivered via colonoscopy. FMT has been used successfully to treat recurrent Clostridium difficile infections, and its potential for other conditions is being explored.
Donors are rigorously screened to ensure they are free from infectious diseases and have a healthy microbiome. The capsules used in the trial are odorless and tasteless, making them easy to swallow.
Potential Impact
If successful, this treatment could offer a safe and affordable option for the millions suffering from long COVID. It could also pave the way for microbiome-based therapies for other post-viral syndromes.
Professor Mark Davis, a gastroenterologist not involved in the trial, commented: 'This is a novel approach that addresses the root cause of some long COVID symptoms. The results will be closely watched by the medical community.'
Safety and Ethics
The trial has received ethics approval and is funded by the National Health and Medical Research Council. Participants will be monitored closely for side effects, which are generally mild and include bloating or temporary changes in bowel habits.
Researchers emphasize that FMT is not a cure-all and should only be performed under medical supervision. Self-administration of faecal transplants at home carries serious risks, including infection.
Looking Ahead
The trial is expected to take 12 months, with preliminary results available by late 2024. If positive, larger studies will be needed before the treatment can become widely available.
For now, participants are hopeful. One anonymous volunteer said: 'I've tried everything for my long COVID symptoms. This gives me hope that I might finally get my life back.'
